NO20063928L - Substituerte kinolinforbindelser - Google Patents

Substituerte kinolinforbindelser

Info

Publication number
NO20063928L
NO20063928L NO20063928A NO20063928A NO20063928L NO 20063928 L NO20063928 L NO 20063928L NO 20063928 A NO20063928 A NO 20063928A NO 20063928 A NO20063928 A NO 20063928A NO 20063928 L NO20063928 L NO 20063928L
Authority
NO
Norway
Prior art keywords
compounds
substituted quinoline
quinoline compounds
compositions
mtp
Prior art date
Application number
NO20063928A
Other languages
English (en)
Inventor
Peter Bertinato
Derek Lawrence Tickner
Michel Andre Couturier
Ernest Selichi Hamanaka
Marcus Douglas Ewing
Jr Ralph Pelton Robinson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20063928L publication Critical patent/NO20063928L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Foreliggende oppfinnelse angår MTP/Apo-B-sekresjonsinhibitorer med formel (I), hvor R1-R7, X1, m og n er som definert i beskrivelsen, så vel som farmasøytiske sammensetninger som innbefatter forbindelsene og fremgangsmåter for anvendelse av forbindelsene og sammensetningene. Forbindelsene ifølge oppfinnelsen er anvendelige ved behandling av fedme og assosiert med sykdommer, tilstander eller forstyrrelser.
NO20063928A 2004-02-04 2006-09-01 Substituerte kinolinforbindelser NO20063928L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54167804P 2004-02-04 2004-02-04
US63376304P 2004-12-06 2004-12-06
PCT/IB2005/000167 WO2005080373A1 (en) 2004-02-04 2005-01-24 Substituted quinoline compounds

Publications (1)

Publication Number Publication Date
NO20063928L true NO20063928L (no) 2006-10-31

Family

ID=34890449

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063928A NO20063928L (no) 2004-02-04 2006-09-01 Substituerte kinolinforbindelser

Country Status (25)

Country Link
US (3) US7468378B2 (no)
EP (1) EP1716137A1 (no)
JP (1) JP2007520543A (no)
KR (1) KR100799802B1 (no)
AP (1) AP2006003685A0 (no)
AR (1) AR047529A1 (no)
AU (1) AU2005214159A1 (no)
BR (1) BRPI0507462A (no)
CA (1) CA2555133A1 (no)
CO (1) CO5700721A2 (no)
CR (1) CR8544A (no)
EA (1) EA010369B1 (no)
EC (1) ECSP066717A (no)
GE (1) GEP20084360B (no)
IL (2) IL176715A0 (no)
MA (1) MA28347A1 (no)
NL (1) NL1028192C2 (no)
NO (1) NO20063928L (no)
OA (1) OA13365A (no)
PA (1) PA8623001A1 (no)
PE (1) PE20050773A1 (no)
SV (1) SV2007002007A (no)
TW (2) TW200906800A (no)
UY (1) UY28734A1 (no)
WO (1) WO2005080373A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5105578B2 (ja) 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
AU2005214159A1 (en) * 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
WO2005100325A1 (en) * 2004-04-14 2005-10-27 Astrazeneca Ab Aryl glycinamide derivatives and their use as nk1 antagonists and serotonin reuptake inhibithors
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
NZ563009A (en) 2005-04-19 2011-05-27 Surface Logix Inc Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
WO2008050199A2 (en) * 2006-10-23 2008-05-02 Pfizer Japan Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
EP2115368A1 (en) * 2007-02-02 2009-11-11 Steve D. Shivvers High efficiency drier with multi stage heating and drying zones
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2009052182A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
CA2958665C (en) 2007-10-19 2021-03-02 Sarcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
WO2010018547A1 (en) * 2008-08-13 2010-02-18 Pfizer Inc. Aminoquinoline compounds
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
CN103906733A (zh) 2011-06-24 2014-07-02 安姆根有限公司 Trpm8拮抗剂及其在治疗中的用途
US9187462B2 (en) * 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
EP3107540A4 (en) * 2014-02-17 2017-08-30 Hetero Research Foundation Polymorphs of lomitapide and its salts
RU2020134082A (ru) 2014-10-06 2020-11-27 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
US10138206B2 (en) 2014-10-09 2018-11-27 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
NZ752486A (en) 2016-09-30 2023-04-28 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
BR112019011626A2 (pt) 2016-12-09 2019-10-22 Vertex Pharma modulador de regulador de condutância transmembrana na fibrose cística, composições farmacêuticas, métodos de tratamento e processo para a produção do modulador
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
MA49752A (fr) 2017-08-02 2021-04-21 Vertex Pharma Procédés de préparation de composés de pyrrolidine
EP3697774A1 (en) 2017-10-19 2020-08-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
WO2019113476A2 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819039A1 (de) 1978-04-29 1979-11-08 Bayer Ag Leimungsmittel fuer papier
HU189569B (en) 1981-03-11 1986-07-28 The Wellcome Foudation Ltd,Gb Process for preparing 2-substituted phenyl/-benzoic acids and pharmaceutical compositons containing such compounds as active substances
EP0580860B2 (en) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
CA2091102C (en) 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE69533408T2 (de) 1994-05-27 2005-09-08 Glaxosmithkline S.P.A. Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
DK0832069T3 (da) 1995-06-07 2003-04-22 Pfizer Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
NZ332341A (en) 1996-05-20 2000-05-26 Darwin Discovery Ltd Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
EP1019378B1 (en) 1996-07-01 2004-09-29 Eli Lilly And Company Hypoglycemic and hypolipidemic compounds
KR100217618B1 (ko) * 1996-12-12 1999-09-01 정몽규 와셔액 분사위치 조절 장치
WO1998027979A1 (en) 1996-12-20 1998-07-02 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
AU755707B2 (en) 1997-12-22 2002-12-19 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
CO5090829A1 (es) 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
CO5271688A1 (es) 1999-11-10 2003-04-30 Pfizer Prod Inc Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
US20020032238A1 (en) 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6417367B1 (en) 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
KR20030067675A (ko) 2000-10-05 2003-08-14 후지사와 야꾸힝 고교 가부시키가이샤 벤자미드 화합물
RS50712B (sr) 2001-06-28 2010-06-30 Pfizer Products Inc. Triamid-supstituisani indoli, benzofurani i benzotiofeni kao inhibitori mikrozomalnog triglicerid transfer proteina (mtp) i/ili sekrecije apolipoproteina b (apo b)
IL161478A0 (en) 2001-10-25 2004-09-27 Takeda Chemical Industries Ltd Quinoline compound
WO2003049685A2 (en) * 2001-12-07 2003-06-19 The Regents Of The University Of California Treatment for age-related macular degeneration
US20030162788A1 (en) 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
MXPA04002602A (es) 2002-02-28 2004-08-11 Japan Tobacco Inc Compuestos de ester y sus usos medicos.
MXPA05006744A (es) * 2002-12-20 2005-09-08 Pfizer Prod Inc Inhibidores de la proteina microsomal de transferencia de trigliceridos.
EP1581499A1 (en) * 2002-12-20 2005-10-05 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
AU2005214159A1 (en) * 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds

Also Published As

Publication number Publication date
ECSP066717A (es) 2006-10-31
TW200906800A (en) 2009-02-16
PA8623001A1 (es) 2006-03-24
JP2007520543A (ja) 2007-07-26
IL208963A0 (en) 2011-07-31
NL1028192C2 (nl) 2006-05-30
US7368573B2 (en) 2008-05-06
EA010369B1 (ru) 2008-08-29
PE20050773A1 (es) 2005-10-26
KR20060127123A (ko) 2006-12-11
US20050234099A1 (en) 2005-10-20
KR100799802B1 (ko) 2008-01-31
AP2006003685A0 (en) 2006-08-31
GEP20084360B (en) 2008-04-29
CA2555133A1 (en) 2005-09-01
MA28347A1 (fr) 2006-12-01
AR047529A1 (es) 2006-01-25
NL1028192A1 (nl) 2005-08-08
AU2005214159A1 (en) 2005-09-01
CO5700721A2 (es) 2006-11-30
CR8544A (es) 2006-11-30
US20060223851A1 (en) 2006-10-05
SV2007002007A (es) 2007-03-20
TWI306454B (en) 2009-02-21
US7393958B2 (en) 2008-07-01
BRPI0507462A (pt) 2007-07-10
EP1716137A1 (en) 2006-11-02
WO2005080373A1 (en) 2005-09-01
EA200601239A1 (ru) 2007-02-27
US20070093525A1 (en) 2007-04-26
OA13365A (en) 2007-04-13
TW200533354A (en) 2005-10-16
US7468378B2 (en) 2008-12-23
IL176715A0 (en) 2006-10-31
UY28734A1 (es) 2005-09-30

Similar Documents

Publication Publication Date Title
NO20063928L (no) Substituerte kinolinforbindelser
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20065456L (no) Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20084005L (no) Aminderivater
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20090327L (no) Nye forbindelser 384
NO20055219L (no) Nye forbindelser
NO20060168L (no) Pyridinylkarbamater som hormonsensitive lipaseinhibitorer
NO20074647L (no) 3,4 dihydro-1H-isoquinolin-2-karboksylsyre-5-ammopyridin-2-yl estere
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
NO20070089L (no) DPP-IV inhibitorer
SE0403006D0 (sv) New compounds
ATE432260T1 (de) Pyridinderivate als pkc-theta-hemmer
AR041297A1 (es) Derivados de 4-pirrolidino- fenil- bencil eter
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
NO20060718L (no) Substituerte tiofoner og deres anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application